VERSEAU THERAPEUTICS INC has a total of 11 patent applications. Its first patent ever was published in 2019. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Brazil. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are VECTORLOGICS INC, M S SWAMINATHAN RES FOUNDATION and ENENKEL BARBARA.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | Australia | 1 | |
#3 | Brazil | 1 | |
#4 | Canada | 1 | |
#5 | EPO (European Patent Office) | 1 | |
#6 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Feldman Igor | 9 |
#2 | Novobrantseva Tatiana | 5 |
#3 | Novobrantseva Tatiana I | 5 |
#4 | Sazinsky Stephen | 3 |
#5 | Wahle Joseph | 3 |
#6 | Phennicie Ryan | 2 |
#7 | O'Nuallain Brian | 2 |
#8 | Kauffman Kevin | 1 |
#9 | Sazinsky Stephen L | 1 |
#10 | Tatiana I Novobrantseva | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020263650A1 | Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
WO2020263651A1 | Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
WO2020247372A1 | Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
WO2020247371A1 | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
WO2020033791A1 | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof | |
AU2019293600A1 | Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof |